Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

'Using research to change paradigms in diagnosing and managing early prostate cancer'


Vincent GnanapragasamVincent Gnanapragasam graduated with BMedSci and MBBS degrees from Newcastle University. Following basic surgical training, he was one of the first trainees to be funded through a Cancer Research UK PhD for Clinicians.  Whilst undertaking Higher Specialist Training in Urology in the North East, Vincent was appointed as Urology First Assistant (Clinical Lecturer) at Newcastle University in 2003. In 2004, supported by the first CRUK Clinician Scientist Fellowship given to a surgeon, Vincent established his own research group.  He is currently a University Lecturer at the University of Cambridge, and Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. Vincent’s current research covers the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. He is CI of the TAPS study (Janssen), NIHR i4i funded CAMPROBE study and national Predict Prostate and PRIM bio-marker study. He is a member of the UK ICGC prostate group and the International Pan Prostate Cancer Collaborative and GAP 3 Active Surveillance consortium. He has developed novel more accurate prognostic prediction models for both group stratified cohorts and for individualised prediction and pioneered risk stratified pathways for active surveillance follow up. To date he has raised over £6M in research grant funding and published over 120 peer reviewed papers. His work has been cited in prostate cancer guidelines by NICE in 2019 and the European Association of Urology in 2018. In the University of Cambridge he (i) leads the University Academic Urology Group, (ii) co-leads the CRUK Cambridge Cancer Centre Urological Malignancies Programme and (iii) established and directs the Cambridge Urology Translational Research and Clinical Trials office. He holds patents and has won numerous prizes for research including the CE Alken prize, Urological Research Society Medial and a Hunterian Professorship. He is also a Visiting Professor at Anglia Ruskin University having established a Master’s research degree programme there for early career aspiring urologists.


Chair: Professor Freddie Hamdy

All members of the University and NHS clinical staff are welcome.